A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas.

Trial Profile

A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral T-cell lymphomas.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Antineoplastics; Cyclophosphamide; Doxorubicin; Granulocyte colony-stimulating factors; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ACE-1; ACT-1
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 May 2017 This trial has been completed in Germany (31 Dec 2016).
    • 24 Mar 2017 Trial is completed in Portugal as reported by European Clinical Trials Database record.(end data 2016-12-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top